ArticleCancer biology & therapy2019

Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.

Yanjun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.